es to watch for signs and symptoms of a severe systemic or a severe local allergic reaction [See Dosage and Administration (2.2)].
Inform parents/guardians that ORALAIR should be administered to children only under adult supervision [See Dosage and Administration (2.2)].
Because of the risk of eosinophilic esophagitis, instruct patients with severe or persistent symptoms of esophagitis to discontinue ORALAIR and to contact their healthcare professional. [See Warnings and Precautions (5.3)]
Asthma
Instruct patients with asthma that if they have difficulty breathing or if asthma becomes difficult to control, they are to stop taking ORALAIR and contact their healthcare professional immediately [See Warnings and Precautions (5.3)].
Administration Instructions
Instruct patients to carefully remove the ORALAIR tablet from the blister just prior to dosing and to take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients to avoid swallowing for about 1 minute, to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet [See Dosage and Administration (2.2)].
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=854c9772-63b9-44a3-a11e-77b29c59e91d
|
